Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
REDEFINE Trial Headlines Trial REDEFINE 1 Phase 3 Duration 68 weeks Population (N) 3,417 adults with obesity or overweight + 1 comorbidity, without T2D Key Result 20.4% mean weight change vs 3.0% placebo (treatment-policy)
Medications should not be the first choice or the only sleep intervention for a paediatric sleep problem
Why Choose DataM
Calculate the draw
There were cured jaundice, weight loss, liver enlargement, microscopy (i.e., piecemeal necrosis, focal lytic necrosis, apoptosis and focal inflammation, and disturbed cell proliferation (Ki-67-staining), cytoskeletal structure in the hepatic stellate cell (-SMA staining), collagen presentation (Mallory staining), and biochemistry presentation (Sever et al., 2019), and counteracted the increased NOS3 expression, interleukin (IL)-6, tumor necrosis factor (TNF)-, and IL-1 levels
US$ 22.35
US$ 24.63
US$ 29.77
US$ 23.28
US$ 26.76
US$ 29.17
US$ 28.01
US$ 20.62
US$ 22.62
US$ 20.82
